{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:50:15Z","timestamp":1771674615279,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00115-023-01502-7","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T14:02:16Z","timestamp":1687356136000},"page":"647-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Angst- und Abh\u00e4ngigkeitserkrankungen\u00a0\u2013 Fokus Alkohol und Cannabis","Anxiety and substance abuse disorders\u2014Focus on alcohol and cannabis"],"prefix":"10.1007","volume":"94","author":[{"given":"Sabine","family":"Hellwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Domschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"1502_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","volume":"19","author":"J Olesen","year":"2012","unstructured":"Olesen\u00a0J, Gustavsson\u00a0A, Svensson\u00a0M et\u00a0al (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19:155\u2013162","journal-title":"Eur J Neurol"},{"key":"1502_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen\u00a0HU, Jacobi\u00a0F, Rehm\u00a0J et\u00a0al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655\u2013679","journal-title":"Eur Neuropsychopharmacol"},{"key":"1502_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","volume":"17","author":"B Bandelow","year":"2015","unstructured":"Bandelow\u00a0B, Michaelis\u00a0S (2015) Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci 17:327\u2013335","journal-title":"Dialogues Clin Neurosci"},{"key":"1502_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jad.2021.10.022","volume":"297","author":"P Xiong","year":"2022","unstructured":"Xiong\u00a0P, Liu\u00a0M, Liu\u00a0B et\u00a0al (2022) Trends in the incidence and DALYs of anxiety disorders at the global, regional, and national levels: Estimates from the Global Burden of Disease Study 2019. J\u00a0Affect Disord 297:83\u201393","journal-title":"J Affect Disord"},{"key":"1502_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","volume":"61","author":"BF Grant","year":"2004","unstructured":"Grant\u00a0BF, Stinson\u00a0FS, Dawson\u00a0DA et al (2004) Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61:807\u2013816","journal-title":"Arch Gen Psychiatry"},{"key":"1502_CR6","first-page":"19","volume":"25","author":"JP Smith","year":"2008","unstructured":"Smith\u00a0JP, Book\u00a0SW (2008) Anxiety and substance use disorders: a review. Psychiatr Times 25:19\u201323","journal-title":"Psychiatr Times"},{"key":"1502_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant\u00a0BF, Goldstein\u00a0RB, Saha\u00a0TD et al (2015) Epidemiology of DSM\u20115 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry 72:757\u2013766","journal-title":"JAMA Psychiatry"},{"key":"1502_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamapsychiatry.2015.2132","volume":"73","author":"BF Grant","year":"2016","unstructured":"Grant\u00a0BF, Saha\u00a0TD, Ruan\u00a0WJ et al (2016) Epidemiology of DSM\u20115 drug use disorder: results from the national epidemiologic survey on alcohol and related conditions-III. JAMA Psychiatry 73:39\u201347","journal-title":"JAMA Psychiatry"},{"key":"1502_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/0706743720952251","volume":"66","author":"S Xue","year":"2021","unstructured":"Xue\u00a0S, Husain\u00a0MI, Zhao\u00a0H et al (2021) Cannabis use and prospective long-term association with anxiety: a systematic review and meta-analysis of longitudinal studies: usage du cannabis et association prospective a\u00a0long terme avec l\u2019anxiete: une revue systematique et une meta-analyse d\u2019etudes longitudinales. Can J Psychiatry 66:126\u2013138","journal-title":"Can J Psychiatry"},{"key":"1502_CR10","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/jamapsychiatry.2020.1035","volume":"77","author":"LA Hines","year":"2020","unstructured":"Hines\u00a0LA, Freeman\u00a0TP, Gage\u00a0SH et al (2020) Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiatry 77:1044\u20131051","journal-title":"JAMA Psychiatry"},{"key":"1502_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jad.2020.12.043","volume":"281","author":"VN Onaemo","year":"2021","unstructured":"Onaemo\u00a0VN, Fawehinmi\u00a0TO, D\u2019arcy\u00a0C (2021) Comorbid cannabis use disorder with major depression and generalized anxiety disorder: a systematic review with meta-analysis of nationally representative epidemiological surveys. J\u00a0Affect Disord 281:467\u2013475","journal-title":"J Affect Disord"},{"key":"1502_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/00952990.2021.1946071","volume":"47","author":"K Kozak","year":"2021","unstructured":"Kozak\u00a0K, Smith\u00a0PH, Lowe\u00a0DJE et al (2021) A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. Am J Drug Alcohol Abuse 47:535\u2013547","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1502_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12888-022-03917-z","volume":"22","author":"NH Som\u00e9","year":"2022","unstructured":"Som\u00e9\u00a0NH, Wells\u00a0S, Felsky\u00a0D et al (2022) Self-reported mental health during the COVID-19 pandemic and its association with alcohol and cannabis use: a\u00a0latent class analysis. BMC Psychiatry 22:306","journal-title":"BMC Psychiatry"},{"key":"1502_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1176\/appi.ajp.162.6.1179","volume":"162","author":"SE Bruce","year":"2005","unstructured":"Bruce\u00a0SE, Yonkers\u00a0KA, Otto\u00a0MW et al (2005) Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a\u00a012-year prospective study. Am J Psychiatry 162:1179\u20131187","journal-title":"Am J Psychiatry"},{"key":"1502_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1192\/bjp.167.1.76","volume":"167","author":"CD Hornig","year":"1995","unstructured":"Hornig\u00a0CD, Mcnally\u00a0RJ (1995) Panic disorder and suicide attempt. A reanalysis of data from the epidemiologic catchment area study. Br J Psychiatry 167:76\u201379","journal-title":"Br J Psychiatry"},{"key":"1502_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2215-0366(15)00092-9","volume":"2","author":"SM Meier","year":"2015","unstructured":"Meier\u00a0SM, Petersen\u00a0L, Mattheisen\u00a0M et al (2015) Secondary depression in severe anxiety disorders: a\u00a0population-based cohort study in Denmark. Lancet Psychiatry 2:515\u2013523","journal-title":"Lancet Psychiatry"},{"key":"1502_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/add.15735","volume":"117","author":"JA Puddephatt","year":"2022","unstructured":"Puddephatt\u00a0JA, Irizar\u00a0P, Jones\u00a0A et al (2022) Associations of common mental disorder with alcohol use in the adult general population: a\u00a0systematic review and meta-analysis. Addiction 117:1543\u20131572","journal-title":"Addiction"},{"key":"1502_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11920-014-0544-y","volume":"17","author":"F Vorspan","year":"2015","unstructured":"Vorspan\u00a0F, Mehtelli\u00a0W, Dupuy\u00a0G et al (2015) Anxiety and substance use disorders: co-occurrence and clinical issues. Curr Psychiatry Rep 17:4","journal-title":"Curr Psychiatry Rep"},{"key":"1502_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1176\/appi.ajp.2021.21030320","volume":"179","author":"KP Hill","year":"2022","unstructured":"Hill\u00a0KP, Gold\u00a0MS, Nemeroff\u00a0CB et\u00a0al (2022) Risks and benefits of cannabis and cannabinoids in psychiatry. Am J Psychiatry 179:98\u2013109","journal-title":"Am J Psychiatry"},{"key":"1502_CR20","first-page":"1","volume":"11","author":"ND Volkow","year":"2012","unstructured":"Volkow\u00a0ND, Wang\u00a0GJ, Fowler\u00a0JS et\u00a0al (2012) Food and drug reward: overlapping circuits in human obesity and addiction. Curr Top Behav Neurosci 11:1\u201324","journal-title":"Curr Top Behav Neurosci"},{"key":"1502_CR21","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.2174\/138161208786848784","volume":"14","author":"K Domschke","year":"2008","unstructured":"Domschke\u00a0K, Zwanzger\u00a0P (2008) GABAergic and endocannabinoid dysfunction in anxiety\u2014future therapeutic targets? Curr Pharm Des 14:3508\u20133517","journal-title":"Curr Pharm Des"},{"key":"1502_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000351938","volume":"29","author":"M Fredrikson","year":"2013","unstructured":"Fredrikson\u00a0M, Faria\u00a0V (2013) Neuroimaging in anxiety disorders. Mod Trends Pharmacopsychiatry 29:47\u201366","journal-title":"Mod Trends Pharmacopsychiatry"},{"key":"1502_CR23","first-page":"13","volume":"22","author":"J Littleton","year":"1998","unstructured":"Littleton\u00a0J (1998) Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World 22:13\u201324","journal-title":"Alcohol Health Res World"},{"key":"1502_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00702-012-0811-1","volume":"120","author":"T Dresler","year":"2013","unstructured":"Dresler\u00a0T, Guhn\u00a0A, Tupak\u00a0SV et\u00a0al (2013) Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder. J\u00a0Neural Transm 120:3\u201329","journal-title":"J Neural Transm"},{"key":"1502_CR25","doi-asserted-by":"publisher","first-page":"e1194","DOI":"10.1038\/tp.2017.161","volume":"7","author":"BM Sharp","year":"2017","unstructured":"Sharp\u00a0BM (2017) Basolateral amygdala and stress-induced hyperexcitability affect motivated behaviors and addiction. Transl Psychiatry 7:e1194","journal-title":"Transl Psychiatry"},{"key":"1502_CR26","doi-asserted-by":"publisher","first-page":"134314","DOI":"10.1016\/j.neulet.2019.134314","volume":"707","author":"M Dong","year":"2019","unstructured":"Dong\u00a0M, Xia\u00a0L, Lu\u00a0M et al (2019) A failed top-down control from the prefrontal cortex to the amygdala in generalized anxiety disorder: evidence from resting-state fMRI with granger causality analysis. Neurosci Lett 707:134314","journal-title":"Neurosci Lett"},{"key":"1502_CR27","doi-asserted-by":"publisher","first-page":"108501","DOI":"10.1016\/j.neuropharm.2021.108501","volume":"188","author":"M Li","year":"2021","unstructured":"Li\u00a0M, Cabrera-Garcia\u00a0D, Salling\u00a0MC et al (2021) Alcohol reduces the activity of somatostatin interneurons in the mouse prefrontal cortex: a neural basis for its disinhibitory effect? Neuropharmacology 188:108501","journal-title":"Neuropharmacology"},{"key":"1502_CR28","doi-asserted-by":"publisher","first-page":"E2657","DOI":"10.1073\/pnas.1206820109","volume":"109","author":"MH Meier","year":"2012","unstructured":"Meier\u00a0MH, Caspi\u00a0A, Ambler\u00a0A et\u00a0al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S\u00a0A 109:E2657\u2013E2664","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl","key":"1502_CR29","first-page":"3","volume":"10","author":"MD Grmek","year":"1988","unstructured":"Grmek\u00a0MD (1988) Medicine and epistemology: transformation of knowledge of health and disease. Hist Philos Life Sci 10(Suppl):3\u20136","journal-title":"Hist Philos Life Sci"},{"key":"1502_CR30","doi-asserted-by":"publisher","unstructured":"Stoychev K, Dilkov D, Naghavi E et al (2021) Genetic basis of dual diagnosis: a review of genome-wide association studies (GWAS) focusing on patients with mood or anxiety disorders and co-occurring alcohol-use disorders. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics11061055","DOI":"10.3390\/diagnostics11061055"},{"key":"1502_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00406-021-01324-1","volume":"272","author":"B Bandelow","year":"2022","unstructured":"Bandelow\u00a0B, Werner\u00a0AM, Kopp\u00a0I et\u00a0al (2022) The German Guidelines for the treatment of anxiety disorders: first revision. Eur Arch Psychiatry Clin Neurosci 272:571\u2013582","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1502_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3389\/fpsyt.2017.00173","volume":"8","author":"C Gimeno","year":"2017","unstructured":"Gimeno\u00a0C, Dorado\u00a0ML, Roncero\u00a0C et\u00a0al (2017) Treatment of comorbid alcohol dependence and anxiety disorder: review of the scientific evidence and recommendations for treatment. Front Psychiatry 8:173","journal-title":"Front Psychiatry"},{"key":"1502_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007505.pub2","author":"JC Ipser","year":"2015","unstructured":"Ipser\u00a0JC, Wilson\u00a0D, Akindipe\u00a0TO et\u00a0al (2015) Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007505.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1502_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3233\/JRS-140616","volume":"26","author":"L Brookwell","year":"2014","unstructured":"Brookwell\u00a0L, Hogan\u00a0C, Healy\u00a0D et al (2014) Ninety-three cases of alcohol dependence following SSRI treatment. Int J Risk Saf Med 26:99\u2013107","journal-title":"Int J Risk Saf Med"},{"key":"1502_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1465-3362.2010.00185.x","volume":"29","author":"LA Ray","year":"2010","unstructured":"Ray\u00a0LA, Heydari\u00a0A, Zorick\u00a0T (2010) Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug Alcohol Rev 29:568\u2013575","journal-title":"Drug Alcohol Rev"},{"key":"1502_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/13543784.2016.1175431","volume":"25","author":"G Martinotti","year":"2016","unstructured":"Martinotti\u00a0G, Orsolini\u00a0L, Fornaro\u00a0M et\u00a0al (2016) Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opin Investig Drugs 25:719\u2013728","journal-title":"Expert Opin Investig Drugs"},{"key":"1502_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/YIC.0000000000000147","volume":"32","author":"MB Generoso","year":"2017","unstructured":"Generoso\u00a0MB, Trevizol\u00a0AP, Kasper\u00a0S et al (2017) Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol 32:49\u201355","journal-title":"Int Clin Psychopharmacol"},{"key":"1502_CR38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1055\/s-0043-122392","volume":"86","author":"U Bonnet","year":"2018","unstructured":"Bonnet\u00a0U, Scherbaum\u00a0N (2018) On the risk of dependence on gabapentinoids. Fortschr Neurol Psychiatr 86:82\u2013105","journal-title":"Fortschr Neurol Psychiatr"},{"key":"1502_CR39","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1345\/aph.1P353","volume":"44","author":"TL Schwartz","year":"2010","unstructured":"Schwartz\u00a0TL, Siddiqui\u00a0UA, Raza\u00a0S et\u00a0al (2010) Acamprosate calcium as augmentation therapy for anxiety disorders. Ann Pharmacother 44:1930\u20131932","journal-title":"Ann Pharmacother"},{"key":"1502_CR40","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1176\/appi.ps.202000189","volume":"72","author":"CN Stanciu","year":"2021","unstructured":"Stanciu\u00a0CN, Brunette\u00a0MF, Teja\u00a0N et\u00a0al (2021) Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: a systematic review. Psychiatr Serv 72:429\u2013436","journal-title":"Psychiatr Serv"},{"key":"1502_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jad.2011.08.004","volume":"139","author":"AL Baker","year":"2012","unstructured":"Baker\u00a0AL, Thornton\u00a0LK, Hiles\u00a0S et al (2012) Psychological interventions for alcohol misuse among people with co-occurring depression or anxiety disorders: a\u00a0systematic review. J\u00a0Affect Disord 139:217\u2013229","journal-title":"J Affect Disord"},{"key":"1502_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/01.ALC.0000163511.24583.33","volume":"29","author":"A Schad\u00e9","year":"2005","unstructured":"Schad\u00e9\u00a0A, Marquenie\u00a0LA, Van Balkom\u00a0AJ et al (2005) The effectiveness of anxiety treatment on alcohol-dependent patients with a\u00a0comorbid phobic disorder: a\u00a0randomized controlled trial. Alcohol Clin Exp Res 29:794\u2013800","journal-title":"Alcohol Clin Exp Res"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-023-01502-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T11:03:42Z","timestamp":1687950222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-023-01502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1502"],"URL":"https:\/\/doi.org\/10.1007\/s00115-023-01502-7","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"3 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>S.\u00a0Hellwig<\/b>: A.\u00a0Finanzielle Interessen: Reisekostenerstattung Vortrag Stuttgart Landes\u00e4rztekammer S\u00fcdbaden.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte \u00c4rztin (Ober\u00e4rztin), Klinik f\u00fcr Psychiatrie und Psychotherapie Freiburg, Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft f\u00fcr Biologische Psychiatrie (DGBP). <b>K.\u00a0Domschke<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Janssen Inc..\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00e4.: Janssen Inc.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: \u00c4rztliche Direktorin Klinik f\u00fcr Psychiatrie und Psychotherapie, Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: Vorstand DGPPN, Vorstand Freiburger Ausbildungsinstitut f\u00fcr Verhaltenstherapie (FAVT).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}